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Venous thromboembolism (VTE) is more prevfalent in cancer patients, with serious adverse consequences, including high rate of cancer ref
currence, long term anticoagulation, poor quality of life 
and death.1 Cancer and its treatment can affect all three 
arms of Virchow’s classical triad of causation of thromf
boembolic disease: alteration in blood flow, damage 
of endothelial cells, and elaboration of procoagulants. 
Cancer can affect blood flow by mechanical effects on 
blood vessels by the tumor as well as by angiogenesis, 
which is induced by many tumors and may cause the 
creation of complexes of blood vessels that are aberrant 
in appearance and have very disordered flow. In fact, 
flow in these vessels can vary not only in magnitude, but 
also in direction.2
Endothelial cells can be damaged directly by tumors 
or by chemotherapy. Procoagulants can be increased on 
the surface of cancer cells, and may also be secreted into 
the bloodstream. Examples of molecules elaborated 
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BACKGROUND: risk factors for cancer-associated Vte include certain cancer types (e.g. pancreatic 
adenocarcinoma), chemotherapy, and the use of erythropoiesis-stimulating agents, central venous catheters, 
and surgery. We studied the risk factors for cancer-associated Vte in our institution.
DESIGN AND SETTING: retrospective analysis of patients with solid cancers treated with chemotherapy at King 
Khalid university hospital from 2000 to 2010.
METHODS: We assessed risk factors responsible for Vte, including performance status, age, chemotherapy, use 
of erythropoietin (epo), stage of disease and use of a central venous catheter. patients with other co-morbidities 
such as diabetes were excluded.
RESULTS:  forty-three (14%) of 306 patients were identified as having Vte, including 111 males and 195 females 
with a median age of 38 years (range, 13-18 years). thirty-nine patients had proximal deep vein thrombosis 
(dVt) and, 4 had pulmonary embolism with no evidence of dVt. of the 43 patients, 40 patients had stage iii or 
iV disease at the time of Vte diagnosis. thirty patients were taking erythropoietin (40 000 units/ week); 25 had a 
hemoglobin level higher than 12 g/dl. all patients were treated with low molecular weight (lmW) heparin and 
maintained on lmW heparin or warfarin for minimum of 6 months. 
CONCLUSION: Vte imposes a great risk to life in cancer patients. risk factors include age more than 40 years, 
advanced cancer stage, chemotherapy, use of epo for anemia and underuse of dVt prophylaxis.
by cancer cells that can predispose to disordered cof
agulation include tissue factor, a vitamin Kfdependent 
cysteine protease that activates factor X, and a mucin 
procoagulant that activates prothrombin. Furthermore, 
chemotherapy treatment can cause a reduction in levels 
of the anticoagulant proteins C and S. Indwelling vef
nous access devices may also predispose to thrombosis 
by altering blood flow, damaging endothelial cells, and 
serving as a foreign surface upon which procoagulants 
can promote thrombosis. In addition, other factors (imf
mobilization, drugs,) can cause dysregulation of the 
normal mechanisms of thrombosis and hemostasis.3
 Hormonal therapy can increase the risk of thromf
boembolic disease. This has been best studied in breast 
cancer where tamoxifen appear to increase the risk for 
venous thrombosis. The increase in risk appears to be 
greatest in postmenopausal patients. An increased risk 
for arterial thrombosis has also been observed.4f8
Erythropoietin (EPO), a glycoprotein hormone, 
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stimulates erythropoesis by binding to the receptors 
of erythroid progenitors. In therapeutic doses (about 
50 units/kg three times weekly), EPO is used in the 
treatment of anemia secondary to chronic renal failure 
(CRF). However, in cancer and chemotherapyfinduced 
anemia, EPO is used in doses up to 500 u/kg weekly. 
An increased incidence of thrombotic events has been 
reported in the literature in patients receiving EPO for 
anemia, particularly when the hemoglobin (Hb) level 
exceeds 120 g/dL. A rise in the absolute Hb level >12 
g/dL or a rate of increase of Hb >1 g/dL every 2 weeks 
sharply increases the incidence of thrombosis.9f11
Various recommendations available in the literature 
for prevention of VTE secondary to EPO treatment 
are as follows: (1) the target Hb level should be 12 g/
dL, (2) the EPO dose should be reduced by 25% if Hb 
level approaches 12 g/dL or increases by >1 g/dL in 
any 2 weeks of the treatment period, (3) if Hb continf
ues to increase >12 g/dL, doses should be suspended 
temporarily and be reinitiated when hemoglobin begins 
to decrease, at a dosage that is 25% lower, (4) dosage 
should be increased by 25% at a frequency of at least 4 
weeks interval, (5) the maximal target Hb level should 
be 12 g/dL, but the goal should be individualized.11
Erythropoietin is a risk factor for VTE as it stimuf
lates both red cell production and tumor growth in paf
tients with breast cancer and head and neck cancer and 
careful monitoring of the Hb level is necessary when 
using red cell production stimulants in other conditions 
(including the anemia induced by cancer, renal failure 
and HIV medications) due to a risk of blood clots that 
could lead to stroke, heart attacks, deep vein thrombof
sis, and pulmonary embolism. The deep vein thrombof
sis risk and pulmonary embolism has also been seen in 
healthy patients receiving the products to control postf
operative anemia.9,10,12
PATIENTS AND METHODS
In this retrospective analysis, we studied all cancer paf
tients with solid tumors treated by chemotherapy at 
King Khalid University Hospital, Riyadh, Saudi Arabia, 
from 2000 to 2010. VTE was confirmed with duplex 
ultrasound of the lower limbs and pelvis. Pulmonary 
embolism (PE) was confirmed with spiral CT scan. The 
site of VTE was either popliteal, femoral, illieal or vena 
caval. All patients with PE had echocardiography to asf
sess for pulmonary hypertension. Dfdimer was done 
on an outpatient basis. Presenting symptoms (pain, 
swelling, dyspnea, cough) or an absence of symptoms, 
whether inpatient or outpatient, and labs at the time, 
were noted. The number of patients receiving thrombof
prophylaxis , type of chemotherapy, performance staf
tus, cofmorbid conditions (eg, diabetes, ischemic heart 
disease), stage of disease, duration of anticoagulation, 
recurrence rates of VTE and overall survival of patients 
with VTE after anticoagulation were studied.
Inclusion criteria were having a solid cancer and ref
ceiving chemotherapy, age 13f85 years, and confirmed 
VTE and PE. Exclusion criteria were being terminal 
palliative supportive, bed bound, having pancreatic 
cancer because of the de novo increase VTE associated 
with pancreatic cancer, and cofmorbidities such as diaf
betes or ischemic heart disease.
RESULTS
Of 306 cancer patients who received chemotherapy, 
165 patients had breast cancer, 73 colon cancer, 45 lung 
cancer and 23 sarcoma. Fortyfthree (14%) patients were 
identified as having VTE, including 165 (53%) with 
breast cancer, 73 (23%) with colon cancer, 45 (14%) 
with lung cancer and 23 (7.5%) sarcoma patients. They 
included 195 (64%) females and 111 (36%) females, 
and the median age was 38 years with 50% older than 
45 years (Table 1). Twofthirds had a performance 
status of 2 or above (Table 2). Thirtyfnine (91%) paf
tients had proximal limb DVT while 4 (9%) had PE 
with or without DVT. Thirtyffour (80%) patients had 
pain and swelling as presenting symptoms. Thirtyfsix 
(84%) patients were diagnosed as having VTE as inpaf
tients and 7 (16%) as outpatient. Forty (93%) patients 
received low molecular heparin while 3 (0.9%) patients 
were receiving heparin followed by longfterm warfarin 
as anticoagulation. 
All 43 patients were receiving chemotherapy. More 
patients (n=11, 25%) were receiving bevacizumab 
than any other agent. Only 3 (0.9%) patients were on 
thromboprophylaxis at the time VTE diagnosis, while 
4 (10%) patients had diabetes. Thirtyfseven (86%) had 
hemoglobin more than 10 g/dL, while 25 (58%) had 
Hb more than 12 g/dL at the time of diagnosis of VTE 
(Table 3). Thirty (70%) patients were receiving EPO 
for anemia, which was started at a dose of 40 000 IU/
week when Hb was less than 10 g/dL and not more 
than 12 g/dL. At the time of diagnosis of VTE, Hb was 
>12 g/dL. Thrombocytopenia or leucopenia were not 
observed to be risk factors for VTE in our study. Forty 
of 43 patients had advanced stage of disease at the time 
of VTE (93%) (Table 4), indicating that an advanced 
stage of disease may be an important risk factor to be 
studied in prospective trials. At 2fyears postfVTE, the 
mortality rate was 88% (38/43).
Although controversial, lifelong VTE treatment 
is recommended after VTE in cancer patients, in our 
study the median time period for anticoagulation was 
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6 months. The recurrence rate in our study was 4%. 
Although studies have shown increased survival post 
low molecular weight heparin, in our study most of 
the patients were advanced stage so overall survival was 
not good as 38 out of 43 (88%) patients who had VTE 
[H1] died at 2 year interval.23,24
In our study, 3 (5%) patients out 56 with perforf
mance status (PS) of zero (0) had VTE and 8 (9%) out 
of 86 had PS 1, 14 (23%) out 60 had PS 2, 13 (16%) 
out of 82 had PS 3 and 5 (23%) out of 22 had PS 4 at 
the time of VTE. Overall 32 (74%) patients with VTE 
had PS 2 or above.
DISCUSSION
Our study was conducted on solid tumor patients who 
received chemotherapy for the purpose of identifying paf
tients with VTE and possible risk factors. Prophylaxis 
against DVT remains the most important factor. An 
increased risk is most generally seen in patients with 
solid tumors. The underlying biologic factors associated 
with the increased risk of thrombosis in patients with 
cancer include the activation of thrombin and fibrin forf
mation both directly by the release of procoagulants by 
tumor cells and indirectly by the activation of endothef
lial cells, leukocytes, and platelets by cytokines and the 
production of a factor Xfactivating cysteine protease, 
mucinous glycoproteins, and circulating tissue factorf
bearing microparticles (Figure 1).2
Despite the evidence for increased risk of VTE 
among patients with cancer and the benefit of prof
phylactic anticoagulation in specific highfrisk settings, 
surveys of oncologists have demonstrated low rates of 
compliance with thromboprophylaxis guidelines.13,14 
The American College of Chest Physicians has recently 
updated general guidelines for VTE prevention, includf
ing a limited discussion of patients with cancer.15 VTE 
prophylaxis is recommended for both surgical patients 
with cancer as well as hospitalized patients considf
ered acutely ill. The National Comprehensive Cancer 
Network provides consensus guidelines on the diagnof
sis and initial evaluation of VTE in patients with canf
cer, available therapies for prophylaxis and treatment of 
VTE and the risks and contraindications of anticoaguf
lation.16 Several international organizations have also 
developed guidelines for patients with cancer at risk for 
VTE.17,18 
Recommendations for VTE prophylaxis by the 
ASCO Guidelines include: (1) hospitalized patients 
with cancer should be considered for VTE prophylaxis 
in the absence of bleeding or other contraindications 
to anticoagulation; (2) routine thromboprophylaxis is 
not recommended in ambulatory patients with canf
Figure 1. Cancer and venous thromboembolism: diagrammatic representation.1
Table 1. Age distribution of all cancer patients and patients with 
venous thromboembolism.
Age (years) All patients Patients with VTE
13-25 26 (8%) 3 (7%)
25-45 123 (40%) 7 (16%)
45-60 95 (31%) 15 (35%)
60-80 45 (15%) 14 (33%)
>80 17 (6%) 4 (9%)
Total 306 43
Values are number (percent).
Table 2. performance status of all cancer patients and patients 
with venous thromboembolism.
Performance 
Status All patients
Patients with 
VTE
0 56 (18%) 3 (7%)
1 86 (28%) 8 (19%)
2 60 (20%) 14 (32%)
3 82 (27%) 13 (30%)
4 22 (7%) 5 (12%)
Total 306 43
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cer, although those with multiple myeloma receiving 
thalidomide or lenalidomide with chemotherapy or 
dexamethasone are at high risk and warrant prophyf
laxis; (3) all patients undergoing major surgical interf
vention for malignant disease should be considered for 
pharmacologic thromboprophylaxis initiated either 
preoperatively, or as early as possible in the postoperaf
tive period. Extended prophylaxis up to 4 weeks and 
combined pharmacologic and mechanical prophylaxis 
may be considered in highfrisk patients; (4) LMWH 
represents the preferred approach for the initial 5 to 10 
days of anticoagulant therapy of patients with cancer 
with established VTE and should be continued for up 
to 6 months for secondary prophylaxis and indefinitely 
in patients with active malignancy; and (5) while anf
ticoagulant treatment in patients with cancer without 
VTE to improve survival is not recommended, patients 
should be encouraged to participate in ongoing clinical 
trials evaluating this issue.16,18
Patients with cancer hospitalized with neutropenia 
and presumed infection with documented thromboemf
bolism have a greater infhospital mortality (P<.001).19 
In our study, only 2 patients had platelets count 
<75×109/L and 2 patients had a WBC count less than 
1000/µL and more than 500/µL, so no association was 
seen in our study of thrombocytopenia or leucopenia 
with VTE.
In a recent study of ambulatory patients with canf
Table 3. Hemoglobin concentration at the time of diagnosis in 
patients with VTE.
Hemoglobin concentration 
(g/dL) No. patients with VTE
<8 0
8-10 6 (14%)
10-12 12 (28%)
>12 25 (58%)
Total 43
Table 4. VTE and stage of cancer.
Stage of cancer
Stage i 0
Stage ii 3 (7%)
Stage iii 23 (53%)
Stage iV 17 (40%)
Total 43
cer who were receiving chemotherapy, of the 3.2% of 
patients who died over the first 3 to 4 cycles of treatf
ment, nearly 10% died of thrombosisfrelated causes.20 
Patients developing symptomatic VTE during chemof
therapy have been found to have a greater risk of early 
mortality (hazard ratio, 4.90; P<.0001) than those 
without VTE.20 Although all chemotherapies are conf
sidered risk factors for VTE, certain biological agents 
in combination with chemotherapy are also proven to 
cause more VTE, like bevacizumab.21 In our study 11 
(25%) patients had bevacizumab while being diagnosed 
as having VTE.
VTE has important impact on overall survival of 
patients. VTE in cancer patients In one study of more 
than 100,000 patients with breast cancer, VTE was a 
significant predictor of decreased 2fyear survival inf
cluding patients with localized disease.22 In our study 
all patients were on active chemotherapy when they def
veloped VTE. Twofyear survival was low as 38 patients 
of 43 who developed VTE were dead at 2 years.
The heparins may influence malignant cell growth 
by inhibiting heparinfbinding growth factors that stimf
ulate malignant cell growth, and by inhibiting tumor 
cell heparinases that influence tumor cell invasion and 
metastasis, as well as cell surface selectinfmediated tuf
mor cell metastasis.23f26 Likewise, studies have demonf
strated that LMW heparins may inhibit angiogenesis, 
block thrombinfinduced platelet aggregation, inhibit 
platelet interaction with vascular endothelium, and 
stimulate platelet production. In our study 40 out of 
43 patients used LMW heparin as anticoagulation post 
VTE.
Erythropoiesisfstimulating agents appear to further 
increase the risk of VTE in patients with cancer.12 In 
our study, of 43 patients with VTE, 30 patients were on 
EPO for anemia and out of these 25 had hemoglobin 
more than 12 mg/dL at the time of VTE, emphasizf
ing need for monitoring of hemoglobin carefully while 
the patient is on EPO for anemia because of the obvif
ous risk of VTE if hemoglobin is more than 12 mg/dL 
while the patient is on active chemotherapy.
 In summary, thrombosis in cancer still poses a great 
challenge. Poor performance status with an advanced 
stage of disease, and a lack of VTE prophylaxis remain 
important risk factors. VTE prophylaxis, although 
recommended, still remains to be implemented in all 
eligible patients. Chemotherapy is a known risk factor, 
but use of EPO during chemotherapy to prevent anef
mia still remains to be studied, especially when the hef
moglobin level is more than 12 mg/dL. We recommend 
watchful use of EPO for anemia in cancer patients while 
on chemotherapy with regular thromboprophylaxis.
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